Tevogen Bio Announces Unique T Cell Vaccine Under Development and Files Patent with the USPTO [Yahoo! Finance]
Tevogen Bio Holdings Inc. (TVGN)
Company Research
Source: Yahoo! Finance
to company's lead product candidate TVGN 489, to mitigate the risk posed by mutations. Approach may provide prophylaxis to viral infections and would be complementary to current treatment under development by Tevogen Bio. Powered by Tevogen Bio's artificial intelligence initiative, Tevogen.AI. The company hopes to address public concerns about inoculation during vaccine development. WARREN, N.J., March 10, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN ), a clinical-stage specialty immunotherapy biotech company, today announced the filing of a new patent with the U.S. Patent and Trademark Office (USPTO) for its under-development T cell vaccine. Unlike many vaccines that primarily induce a
Read more
Impact Snapshot
Event Time:
TVGN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TVGN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TVGN alerts
High impacting Tevogen Bio Holdings Inc. news events
Weekly update
A roundup of the hottest topics
TVGN
News
- Tevogen Bio CEO Named to NJBIZ 2025 Health Care Power List as Company Advances Commercialization; Reaffirms Timeframe on Previously Announced ForecastGlobeNewswire
- Tevogen Bio Appoints David E. Banko as Global Head of Government Affairs and Patient Access, Advances Commercialization PlanGlobeNewswire
- Tevogen Bio Holdings Inc. (NASDAQ: TVGN) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $10.00 price target on the stock.MarketBeat
- Tevogen Bio Announces Unique T Cell Vaccine Under Development and Files Patent with the USPTOGlobeNewswire
- Tevogen Bio's CIO & Head of Tevogen.AI, Mittul Mehta, Featured Speaker at Proskauer's AI Discussion Panel [Yahoo! Finance]Yahoo! Finance
TVGN
Sec Filings
- 3/14/25 - Form 4
- 3/11/25 - Form 4
- 3/6/25 - Form 4
- TVGN's page on the SEC website